Contrast-enhanced sonography in pancreatic diseases

Rickes, Steffen; Rauh, Peter; Uhle, Christine; Ensberg, Daniel; Mönkemüller, Klaus; Malfertheiner, Peter

doi:10.1016/j.ejrad.2007.06.035

Cited by 24 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As is known from a Pancreatic Multicenter Ultrasound Study (PAMUS), ductal adenocarcinomas are typically hypovascular and with a hypoenhanced mass due to the prominent desmoplasia and fibrosis, and if the typical hypoenhanced pattern of ductal adenocarcinoma is not present, another diagnosis has to be made, such as neuroendocrine lesion and metastases [1,2,33]. In this meta-analysis, the overall sensitivity 0.…”

Section: Discussionmentioning

confidence: 99%

“…Thirteen studies were on the subject of diagnosis [12][13][14][15][16][17][20][21][23][24][25][27][28][29][30][32][33] and 5 studies were concerned with suspicion in the clinical setting [18][19]22,26,31]. In these studies 2704 patients were enrolled while 2664 were included in the analysis.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…The contrast-enhanced phase is observed after the injection of a intravascular contrast media and the pancreatic tumor vascularization is visible by CEUS. With the help of harmonic microbubble-specific software, the contrast media produces a hyper echoic signal in the regions where the vessels are present, and the non-vascularized tissue remains non-enhancing, thus making a differential diagnosis possible [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Contrast-Enhanced Ultrasound for differential diagnosis of pancreatic mass lesions: a meta-analysis.

Lin

Liu

et al. 2016

Med Ultrason

View full text Add to dashboard Cite

Aim: To evaluate the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) as a method for diagnosing pancreatic lesions with regard to the ductal pancreatic carcinoma and the differentiation of neoplastic from non-neoplastic lesions. Material and methods: Relevant studies published by September 6, 2015 were retrieved from PubMed, Embase, and Cochrane Central Trials databases. The articles included were mainly based on the following criteria: use of CEUS as the diagnostic tool, and the use of histology as the reference method. Two independent reviewers inspected all these papers to confirm the matching of the inclusion criteria. One reviewer with methodological expertise extracted the data from the included studies. Sensitivity, specificity and diagnostic odds ratio (DOR) were used to obtain overall estimates. Results: Eighteen studies out of 734 articles initially identified met the inclusion criteria. The primary study objective with respect to ductal adenocarcinoma was verified in 15 studies. The pooled estimate of CEUS sensitivity for the differential diagnosis of duct adenocarcinomas was 0.90 (95 % CI, 0.89-0.92), and the specificity was 0.88 (0.84-0.90). The pooled estimate for DOR was 56.38 (29.91-106.33). The area under the curve under the summary receiver operating characteristic (SROC) was 0.95. 12 out of 18 studies examined CEUS sensitivity and the average specificity with regard to the secondary study objective, distinguishing between neoplastic lesions and non-neoplastic lesions, were 0.95 (0.94-0.96) and 0.83 (0.77-0.87). The pooled estimate for DOR was 73. 25(45.31-118.43). The area under the SROC curve was 0.96. Conclusions: CEUS is a promising, reliable modality for the differential diagnosis of pancreatic adenocarcinoma in patients with pancreatic mass lesions. The presence of a hypoenhanced lesion was a sensitive predictor of pancreatic adenocarcinomas. It seems to be a useful tool in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Contrast-Enhanced Ultrasound for differential diagnosis of pancreatic mass lesions: a meta-analysis.

Lin

Liu

et al. 2016

Med Ultrason

View full text Add to dashboard Cite

show abstract

“…Additionally, promising results for the localization and differential diagnosis of PNETs were recently reported for a contrast-enhanced ultrasound approach (CEUS) [95,96]. Somatostatin receptor scintigraphy (SRS) is positive in 46% of all benign insulinomas.…”

Section: Insulinomamentioning

confidence: 99%

Neuroendocrine Tumors of the Pancreas

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Currently, a number of published papers describe the CEUS enhancement pattern of the most common benign and malign pancreatic lesions [3,[8][9][10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

The value of Contrast-Enhanced Ultrasound in the characterization of vascular pattern of solid pancreatic lesions

et al. 2015

View full text Add to dashboard Cite

The aim of our study was to evaluate the accuracy of CEUS in the characterization of pancreatic solid lesions, considering cross sectional imaging techniques (CE-CT/MRI) as the "gold standard" methods. Material and methods: We performed a retrospective, monocentric study that included 91 solid pancreatic lesions which were evaluated by CEUS and by a secondline contrast imaging technique (CT or MRI), considered as the reference method. Results: The rate of a conclusive diagnosis based on a typical enhancement pattern was 94% (78/83 cases). In 72 cases out of 83 (86.7%) there was a perfect concordance between CEUS and the "gold-standard" imaging method (CE-CT/MRI). In our study, 88% (73/83) of the pancreatic lesions were categorized as malignant due to their typical wash-out aspect in the late phase. The overall accuracy of CEUS for the differential diagnosis of solid pancreatic tumors was approximately 81%. The accuracy of CEUS for the diagnosis of hypoenhancing pancreatic tumors was approximately 89.1%; while for the diagnosis of hyperenhancing pancreatic tumors it was approximately 72.8%. Conclusion: CEUS allows the differentiation between hypo-vs. hyperenhancing pancreatic solid lesions, with a considerable diagnostic accuracy, a fundamental step in the precise diagnosis of pancreatic tumors.

show abstract

Contrast-enhanced sonography in pancreatic diseases

Cited by 24 publications

References 23 publications

Contrast-Enhanced Ultrasound for differential diagnosis of pancreatic mass lesions: a meta-analysis.

Contrast-Enhanced Ultrasound for differential diagnosis of pancreatic mass lesions: a meta-analysis.

Neuroendocrine Tumors of the Pancreas

The value of Contrast-Enhanced Ultrasound in the characterization of vascular pattern of solid pancreatic lesions

Contact Info

Product

Resources

About